Toshinari Yamashita

机构：Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center · ORCID：0000-0002-6479-1660

发表论文 269 篇 · 总被引 11813 次 · h-index 33

代表论文

• Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer (2025 · New England Journal of Medicine · 被引 60)
• Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial (2025 · Annals of Oncology · 被引 4)
• AdipoR1–AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis (2026 · Cell Death and Disease · 被引 1)
• Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer (2025 · Endocrine Related Cancer · 被引 1)
• Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD (2026 · Breast Cancer Research and Treatment)
• Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer (2026 · Breast Cancer)